View Financial HealthFermentalg 配当と自社株買い配当金 基準チェック /06Fermentalg配当金を支払った記録がありません。主要情報n/a配当利回り0.04%バイバック利回り総株主利回り0.04%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 15Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million.Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,725,985 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listingお知らせ • May 14Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million.Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,000,000 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listingお知らせ • May 07Fermentalg SA, Annual General Meeting, Jun 11, 2026Fermentalg SA, Annual General Meeting, Jun 11, 2026. Location: 4 rue riviere, libourne FranceBreakeven Date Change • Apr 07Forecast to breakeven in 2028The 2 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 48% per year to 2027. The company is expected to make a profit of €1.30m in 2028. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Reported Earnings • Apr 05Full year 2025 earnings released: €0.09 loss per share (vs €0.17 loss in FY 2024)Full year 2025 results: €0.09 loss per share (improved from €0.17 loss in FY 2024). Revenue: €14.9m (up 30% from FY 2024). Net loss: €9.44m (loss narrowed 27% from FY 2024). Revenue is forecast to grow 41% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.New Risk • Apr 04New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.6m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€46.4m market cap, or US$53.4m).New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€4.5m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€40.7m market cap, or US$48.7m).お知らせ • Jan 17+ 5 more updatesFermentalg SA to Report Fiscal Year 2025 Final Results on Apr 02, 2026Fermentalg SA announced that they will report fiscal year 2025 final results at 5:40 PM, Central European Standard Time on Apr 02, 2026Breakeven Date Change • Oct 13Forecast to breakeven in 2027The 2 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2026. The company is expected to make a profit of €1.20m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule.Reported Earnings • Sep 14First half 2025 earnings released: €0.04 loss per share (vs €0.095 loss in 1H 2024)First half 2025 results: €0.04 loss per share (improved from €0.095 loss in 1H 2024). Revenue: €7.61m (up 20% from 1H 2024). Net loss: €4.33m (loss narrowed 24% from 1H 2024). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Breakeven Date Change • Sep 12No longer forecast to breakevenThe 2 analysts covering Fermentalg no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.30m in 2027. New consensus forecast suggests the company will make a loss of €1.80m in 2027.Breakeven Date Change • May 13Forecast to breakeven in 2027The 2 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 40% per year to 2026. The company is expected to make a profit of €1.30m in 2027. Average annual earnings growth of 68% is required to achieve expected profit on schedule.お知らせ • May 08Fermentalg SA, Annual General Meeting, Jun 12, 2025Fermentalg SA, Annual General Meeting, Jun 12, 2025. Location: 4 rue riviere, libourne FranceNew Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (109% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.2m net loss in 2 years). Market cap is less than US$100m (€36.1m market cap, or US$40.9m).Reported Earnings • Mar 26Full year 2024 earnings released: €0.17 loss per share (vs €0.32 loss in FY 2023)Full year 2024 results: €0.17 loss per share (improved from €0.32 loss in FY 2023). Revenue: €11.5m (up 183% from FY 2023). Net loss: €12.9m (loss narrowed 9.0% from FY 2023). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.お知らせ • Jan 15Fermentalg SA to Report Fiscal Year 2024 Results on Mar 20, 2025Fermentalg SA announced that they will report fiscal year 2024 results After-Market on Mar 20, 2025Reported Earnings • Oct 12First half 2024 earnings released: €0.095 loss per share (vs €0.13 loss in 1H 2023)First half 2024 results: €0.095 loss per share (improved from €0.13 loss in 1H 2023). Revenue: €6.32m (up 170% from 1H 2023). Net loss: €5.66m (flat on 1H 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 5.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 105% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.3m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (€4.1m revenue, or US$4.3m). Market cap is less than US$100m (€36.2m market cap, or US$38.8m).お知らせ • May 09Fermentalg SA, Annual General Meeting, Jun 11, 2024Fermentalg SA, Annual General Meeting, Jun 11, 2024. Location: 4 rue riviere, libourne FranceNew Risk • Apr 09New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: €4.1m (US$4.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€11m net loss next year). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.4m). Market cap is less than US$100m (€25.5m market cap, or US$27.7m).Reported Earnings • Apr 04Full year 2023 earnings released: €0.32 loss per share (vs €0.24 loss in FY 2022)Full year 2023 results: €0.32 loss per share (further deteriorated from €0.24 loss in FY 2022). Revenue: €5.12m (down 33% from FY 2022). Net loss: €14.1m (loss widened 43% from FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Jan 23+ 4 more updatesFermentalg SA to Report Fiscal Year 2023 Results on Apr 03, 2024Fermentalg SA announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 03, 2024New Risk • Sep 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$27.3m).Board Change • Aug 29Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helene Moncorger-Pilicer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.8m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€26.6m market cap, or US$29.2m).Board Change • Jul 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helene Moncorger-Pilicer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 22Full year 2022 earnings released: €0.24 loss per share (vs €0.19 loss in FY 2021)Full year 2022 results: €0.24 loss per share (further deteriorated from €0.19 loss in FY 2021). Revenue: €9.04m (up 60% from FY 2021). Net loss: €9.87m (loss widened 44% from FY 2021). Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.お知らせ • Feb 15+ 5 more updatesFermentalg SA to Report Fiscal Year 2022 Results on Apr 20, 2023Fermentalg SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Apr 20, 2023Board Change • Jan 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Oct 03First half 2022 earnings released: €0.13 loss per share (vs €0.17 loss in 1H 2021)First half 2022 results: €0.13 loss per share. Revenue: €5.68m (up 77% from 1H 2021). Net loss: €5.44m (loss widened 14% from 1H 2021). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Jul 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 27Full year 2021 earnings released: €0.19 loss per share (vs €0.32 loss in FY 2020)Full year 2021 results: €0.19 loss per share (up from €0.32 loss in FY 2020). Revenue: €6.80m (up 86% from FY 2020). Net loss: €6.85m (flat on FY 2020). Over the next year, revenue is forecast to grow 45% compared to a 14% decline forecast for the industry in the United Kingdom.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 23Full year 2021 earnings released: €0.19 loss per share (vs €0.32 loss in FY 2020)Full year 2021 results: €0.19 loss per share (up from €0.32 loss in FY 2020). Revenue: €6.80m (up 86% from FY 2020). Net loss: €6.85m (flat on FY 2020). Over the next year, revenue is forecast to grow 45% compared to a 14% decline forecast for the industry in the United Kingdom.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 23First half 2021 earnings released: €0.17 loss per share (vs €0.23 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: €3.21m (up 67% from 1H 2020). Net loss: €4.76m (loss widened 7.1% from 1H 2020).Reported Earnings • Apr 18Full year 2020 earnings released: €0.32 loss per share (vs €0.97 loss in FY 2019)Full year 2020 results: Net loss: €6.88m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has remained flat, which means it is well ahead of earnings.決済の安定と成長配当データの取得安定した配当: 0QTJの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 0QTJの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Fermentalg 配当利回り対市場0QTJ 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (0QTJ)n/a市場下位25% (GB)2.2%市場トップ25% (GB)5.6%業界平均 (Chemicals)3.9%アナリスト予想 (0QTJ) (最長3年)0%注目すべき配当: 0QTJは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 0QTJは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 0QTJの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 0QTJが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YGB 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 20:02終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fermentalg SA 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Fanny MeindreCIC Market Solutions (ESN)Guillaume CuvillierGilbert DupontStephanie LefebvreGilbert Dupont5 その他のアナリストを表示
お知らせ • May 15Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million.Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,725,985 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listing
お知らせ • May 14Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million.Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,000,000 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listing
お知らせ • May 07Fermentalg SA, Annual General Meeting, Jun 11, 2026Fermentalg SA, Annual General Meeting, Jun 11, 2026. Location: 4 rue riviere, libourne France
Breakeven Date Change • Apr 07Forecast to breakeven in 2028The 2 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 48% per year to 2027. The company is expected to make a profit of €1.30m in 2028. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Reported Earnings • Apr 05Full year 2025 earnings released: €0.09 loss per share (vs €0.17 loss in FY 2024)Full year 2025 results: €0.09 loss per share (improved from €0.17 loss in FY 2024). Revenue: €14.9m (up 30% from FY 2024). Net loss: €9.44m (loss narrowed 27% from FY 2024). Revenue is forecast to grow 41% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
New Risk • Apr 04New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.6m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€46.4m market cap, or US$53.4m).
New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€4.5m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€40.7m market cap, or US$48.7m).
お知らせ • Jan 17+ 5 more updatesFermentalg SA to Report Fiscal Year 2025 Final Results on Apr 02, 2026Fermentalg SA announced that they will report fiscal year 2025 final results at 5:40 PM, Central European Standard Time on Apr 02, 2026
Breakeven Date Change • Oct 13Forecast to breakeven in 2027The 2 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2026. The company is expected to make a profit of €1.20m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
Reported Earnings • Sep 14First half 2025 earnings released: €0.04 loss per share (vs €0.095 loss in 1H 2024)First half 2025 results: €0.04 loss per share (improved from €0.095 loss in 1H 2024). Revenue: €7.61m (up 20% from 1H 2024). Net loss: €4.33m (loss narrowed 24% from 1H 2024). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Sep 12No longer forecast to breakevenThe 2 analysts covering Fermentalg no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.30m in 2027. New consensus forecast suggests the company will make a loss of €1.80m in 2027.
Breakeven Date Change • May 13Forecast to breakeven in 2027The 2 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 40% per year to 2026. The company is expected to make a profit of €1.30m in 2027. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
お知らせ • May 08Fermentalg SA, Annual General Meeting, Jun 12, 2025Fermentalg SA, Annual General Meeting, Jun 12, 2025. Location: 4 rue riviere, libourne France
New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (109% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.2m net loss in 2 years). Market cap is less than US$100m (€36.1m market cap, or US$40.9m).
Reported Earnings • Mar 26Full year 2024 earnings released: €0.17 loss per share (vs €0.32 loss in FY 2023)Full year 2024 results: €0.17 loss per share (improved from €0.32 loss in FY 2023). Revenue: €11.5m (up 183% from FY 2023). Net loss: €12.9m (loss narrowed 9.0% from FY 2023). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
お知らせ • Jan 15Fermentalg SA to Report Fiscal Year 2024 Results on Mar 20, 2025Fermentalg SA announced that they will report fiscal year 2024 results After-Market on Mar 20, 2025
Reported Earnings • Oct 12First half 2024 earnings released: €0.095 loss per share (vs €0.13 loss in 1H 2023)First half 2024 results: €0.095 loss per share (improved from €0.13 loss in 1H 2023). Revenue: €6.32m (up 170% from 1H 2023). Net loss: €5.66m (flat on 1H 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 5.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 105% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.3m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (€4.1m revenue, or US$4.3m). Market cap is less than US$100m (€36.2m market cap, or US$38.8m).
お知らせ • May 09Fermentalg SA, Annual General Meeting, Jun 11, 2024Fermentalg SA, Annual General Meeting, Jun 11, 2024. Location: 4 rue riviere, libourne France
New Risk • Apr 09New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: €4.1m (US$4.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€11m net loss next year). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.4m). Market cap is less than US$100m (€25.5m market cap, or US$27.7m).
Reported Earnings • Apr 04Full year 2023 earnings released: €0.32 loss per share (vs €0.24 loss in FY 2022)Full year 2023 results: €0.32 loss per share (further deteriorated from €0.24 loss in FY 2022). Revenue: €5.12m (down 33% from FY 2022). Net loss: €14.1m (loss widened 43% from FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Jan 23+ 4 more updatesFermentalg SA to Report Fiscal Year 2023 Results on Apr 03, 2024Fermentalg SA announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 03, 2024
New Risk • Sep 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$27.3m).
Board Change • Aug 29Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helene Moncorger-Pilicer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.8m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€26.6m market cap, or US$29.2m).
Board Change • Jul 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helene Moncorger-Pilicer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 22Full year 2022 earnings released: €0.24 loss per share (vs €0.19 loss in FY 2021)Full year 2022 results: €0.24 loss per share (further deteriorated from €0.19 loss in FY 2021). Revenue: €9.04m (up 60% from FY 2021). Net loss: €9.87m (loss widened 44% from FY 2021). Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.
お知らせ • Feb 15+ 5 more updatesFermentalg SA to Report Fiscal Year 2022 Results on Apr 20, 2023Fermentalg SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Apr 20, 2023
Board Change • Jan 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Oct 03First half 2022 earnings released: €0.13 loss per share (vs €0.17 loss in 1H 2021)First half 2022 results: €0.13 loss per share. Revenue: €5.68m (up 77% from 1H 2021). Net loss: €5.44m (loss widened 14% from 1H 2021). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Jul 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 27Full year 2021 earnings released: €0.19 loss per share (vs €0.32 loss in FY 2020)Full year 2021 results: €0.19 loss per share (up from €0.32 loss in FY 2020). Revenue: €6.80m (up 86% from FY 2020). Net loss: €6.85m (flat on FY 2020). Over the next year, revenue is forecast to grow 45% compared to a 14% decline forecast for the industry in the United Kingdom.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 23Full year 2021 earnings released: €0.19 loss per share (vs €0.32 loss in FY 2020)Full year 2021 results: €0.19 loss per share (up from €0.32 loss in FY 2020). Revenue: €6.80m (up 86% from FY 2020). Net loss: €6.85m (flat on FY 2020). Over the next year, revenue is forecast to grow 45% compared to a 14% decline forecast for the industry in the United Kingdom.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 23First half 2021 earnings released: €0.17 loss per share (vs €0.23 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: €3.21m (up 67% from 1H 2020). Net loss: €4.76m (loss widened 7.1% from 1H 2020).
Reported Earnings • Apr 18Full year 2020 earnings released: €0.32 loss per share (vs €0.97 loss in FY 2019)Full year 2020 results: Net loss: €6.88m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has remained flat, which means it is well ahead of earnings.